These results and findings further convinced that HHT combined with gilteritinib upregulated UBE2L6, which increased the degradation of Mcl-1 and then initiating the apoptosis of FLT3-ITD mutant AML cells. The gene discussed is UBE2L6; the disease is acute myeloid leukemia.